Artificial Intelligence | Machine Learning | Natural Language Processing Oxford Drug Design | AI-Based Drug Discovery


Enterprise, Oncology Therapeutics, Anti-Cancer Drugs, tRNA Synthetases, Small Molecules Oxford, England, United Kingdom

Oxford Drug Design

Artificial Intelligence | Machine Learning | Natural Language Processing


Oxford Drug Design | AI-Based Drug Discovery

Oxford Drug Design

Oncology Therapeutics, Anti-Cancer Drugs, tRNA Synthetases, Small Molecules


Oxford, England, United Kingdom

Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We are discovering new drugs with differentiated modes of action against challenging diseases with high unmet medical needs. Based on a core competence platform in tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. Our differentiated drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action against urgent pathogens.

The strong drug design and development expertise of Oxford Drug Design results from a distinctive combination of our two core competencies. Comprehensive capabilities in aminoacyl-tRNA synthetases (aaRS). Pioneering computational AI and machine learning methods. Each is distinctive in its own right, yet the seamless in-house integration of the two complementary strengths produces an even deeper and more differentiated capability.

 

 
 

   Total Funding: N/A

   Funding Stage: N/A

   Business Stage: Scaling Up

   Market: B2B

   Company Size: 1 to 25

   Founded: 2017

 
 

Date

Round

$ Raised

Investors

05/19/2022

Funded

$2.7M

ACF Investors, O2h Ventures

Date : 05/19/2022

Round: Funded

$ Raised: $2.7M

Investors: ACF Investors, O2h Ventures

 

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Oxford Drug Design

 
 
 
Alan Roth

Alan Roth
Chief Executive Officer

Paul Finn

Paul Finn
Chief Scientific Officer

Graham Richards

Graham Richards
Chairperson

 
 

Oxford Drug Design is growing. Want to work at Oxford Drug Design? Oxford Drug Design is hiring. Join team at Oxford Drug Design

 
 
appengine.ai

World's Most Promising AI/ML Startups